A comprehensive view of Merck & Co. Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
European Commission approves Merck’s KEYTRUDA pembrolizumab plus chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults
Published:
March 28, 2024
by Business Wire
|
Merck & Co. Inc. Announces FDA Approval for Pulmonary Arterial Hypertension Treatment, Reinforcing Commitment to PAH Patients and Advancing Clinical Trial Diversity
Published:
March 27, 2024
by Industry Intelligence Inc.
|
Merck's second trial testing Lynparza with Keytruda to treat metastatic non-small cell lung cancer fails to show significant improvement on life expectancy or disease progression; Merck remains committed to exploring Keytruda combinations in lung cancer
Published:
March 21, 2024
by FiercePharma
|
Merck announces plans to develop a new multi-valent HPV vaccine offering broader protection against multiple HPV types; the company will also initiate clinical trials to test the efficacy and safety of a single-dose regimen of Gardasil 9
Published:
March 15, 2024
by PharmaBiz
|
GlobalData expects GLP-1 drugs like Novo Nordisk's Ozempic to become bestselling drug class in 2024, dethroning PD-1 inhibitors like Merck's Keytruda; GLP-1 drugs' expected annual sales of US$50B marks shift in demand from oncology to metabolic disorders
Published:
March 15, 2024
by FiercePharma
|
Ask us about our R&D/Patents market view